A Dynamic Bayesian Network model for simulation of disease progression in Amyotrophic Lateral Sclerosis patients
- Published
- Accepted
- Subject Areas
- Bioinformatics, Computational Biology, Data Mining and Machine Learning, Scientific Computing and Simulation
- Keywords
- Dynamic Bayesian Network, Amyotrophic Lateral Sclerosis, data mining, simulation, disease progression, biomarkers
- Copyright
- © 2017 Zandonà et al.
- Licence
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ Preprints) and either DOI or URL of the article must be cited.
- Cite this article
- 2017. A Dynamic Bayesian Network model for simulation of disease progression in Amyotrophic Lateral Sclerosis patients. PeerJ Preprints 5:e3262v1 https://doi.org/10.7287/peerj.preprints.3262v1
Abstract
Background. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease primarily affecting upper and lower motor neurons in the brain and spinal cord. The heterogeneity in the course of ALS clinical progression and ultimately survival, coupled with the rarity of this disease, make predicting disease outcome at the level of the individual patient very challenging. Besides, stratification of ALS patients has been known for years as a question of great importance to clinical practice, research and drug development.
Methods. In this work, we present a Dynamic Bayesian Network (DBN) model of ALS progression to detect probabilistic relationships among variables included in the Pooled Resource Open-Access ALS Clinical Trials Database (PRO-ACT), which provides records of over 10,700 patients from different clinical trials, and with over 2,869,973 longitudinally collected data measurements.
Results. Our model unravels new dependencies among clinical variables in relation to ALS progression, such as the influence of basophil count and creatine kinase on patients’ clinical status and the respiratory functional state, respectively. Furthermore, it provided an indication of ALS temporal evolution, in terms of the most probable disease trajectories across time at the level of both patient population and individual patient.
Conclusions. The risk factors identified by out DBN model could allow patients' stratification based on velocity of disease progression and a sensitivity analysis on this latter in response to changes in input variables, i.e. variables measured at diagnosis.
Author Comment
This is an abstract which has been accepted for the NETTAB 2017 Workshop “Methods, tools & platforms for Personalized Medicine in the Big Data Era”.